Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for Voyager Therapeutics (VYGR) over the last 9 years, with Sep 2024 value amounting to $56.4 million.

  • Voyager Therapeutics' Total Non-Current Liabilities fell 43.36% to $56.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $56.4 million, marking a year-over-year decrease of 43.36%. This contributed to the annual value of $96.9 million for FY2023, which is 22.55% up from last year.
  • As of Q3 2024, Voyager Therapeutics' Total Non-Current Liabilities stood at $56.4 million, which was down 5.44% from $59.6 million recorded in Q2 2024.
  • Over the past 5 years, Voyager Therapeutics' Total Non-Current Liabilities peaked at $211.8 million during Q1 2020, and registered a low of $56.3 million during Q3 2021.
  • Over the past 3 years, Voyager Therapeutics' median Total Non-Current Liabilities value was $96.8 million (recorded in 2023), while the average stood at $88.1 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first slumped by 72.44% in 2021, then spiked by 88.68% in 2022.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Total Non-Current Liabilities stood at $62.9 million in 2020, then dropped by 5.83% to $59.2 million in 2021, then surged by 33.54% to $79.0 million in 2022, then grew by 22.55% to $96.9 million in 2023, then crashed by 43.36% to $56.4 million in 2024.
  • Its last three reported values are $56.4 million in Q3 2024, $59.6 million for Q2 2024, and $85.7 million during Q1 2024.